DCM
MCID: DLT002
MIFTS: 79

Dilated Cardiomyopathy (DCM)

Categories: Blood diseases, Bone diseases, Cardiovascular diseases, Ear diseases, Genetic diseases, Immune diseases, Neuronal diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Dilated Cardiomyopathy

MalaCards integrated aliases for Dilated Cardiomyopathy:

Name: Dilated Cardiomyopathy 12 74 24 52 58 36 29 54 6 15 37 17 32
Familial Dilated Cardiomyopathy 12 74 52 25 58 29 6 71
Idiopathic Dilation Cardiomyopathy 12 74 71
Primary Dilated Cardiomyopathy 12 29 6
Cardiomyopathy, Dilated 43 39 71
Idiopathic Dilated Cardiomyopathy 52 17
Congestive Cardiomyopathy 12 25
Dcm 52 47
Hypokinetic Dilated Cardiomyopathy, Familial 52
Primary Familial Dilated Cardiomyopathy 25
Cardiomyopathy, Familial Idiopathic 71
Familial Idiopathic Cardiomyopathy 25
Cardiomyopathy, Familial Dilated 52
Dilated Cardiomyopathy, Familial 52
Fdc 25

Characteristics:

Orphanet epidemiological data:

58
dilated cardiomyopathy
Age of onset: All ages;

Classifications:



External Ids:

Disease Ontology 12 DOID:12930
KEGG 36 H00294
MeSH 43 D002311
NCIt 49 C84673
SNOMED-CT 67 74368002
ICD10 32 I42.0
MESH via Orphanet 44 C536231 D002311
ICD10 via Orphanet 33 I42.0
UMLS via Orphanet 72 C0007193 C0340427
UMLS 71 C0007193 C0340427 C1449563 more

Summaries for Dilated Cardiomyopathy

KEGG : 36 Dilated cardiomyopathy (DCM) is a heart muscle disease characterised by dilation and impaired contraction of the left or both ventricles that results in progressive heart failure and sudden cardiac death from ventricular arrhythmia. Genetically inherited forms of DCM ("familial" DCM) have been identified in 25-35% of patients presenting with this disease, and the inherited gene defects are an important cause of "familial" DCM. The pathophysiology may be separated into two categories: defects in force generation and defects in force transmission. In cases where an underlying pathology cannot be identified, the patient is diagnosed with an "idiopathic" DCM. Current hypotheses regarding causes of "idiopathic" DCM focus on myocarditis induced by enterovirus and subsequent autoimmune myocardium impairments. Antibodies to the beta1-adrenergic receptor (beta1AR), which are detected in a substantial number of patients with "idiopathic" DCM, may increase the concentration of intracellular cAMP and intracellular Ca2+, a condition often leading to a transient hyper-performance of the heart followed by depressed heart function and heart failure.

MalaCards based summary : Dilated Cardiomyopathy, also known as familial dilated cardiomyopathy, is related to familial isolated dilated cardiomyopathy and cardiomyopathy, dilated, 1e. An important gene associated with Dilated Cardiomyopathy is LMNA (Lamin A/C), and among its related pathways/superpathways are Dilated cardiomyopathy (DCM) and Cardiac conduction. The drugs Verapamil and Benazepril have been mentioned in the context of this disorder. Affiliated tissues include Heart, and related phenotypes are failure to thrive and dyspnea

Disease Ontology : 12 An intrinsic cardiomyopathy that is characterized by an an enlarged heart and damage to the myocardium causing the heart to pump blood inefficiently.

Genetics Home Reference : 25 Familial dilated cardiomyopathy is a genetic form of heart disease. It occurs when heart (cardiac) muscle becomes thin and weakened in at least one chamber of the heart, causing the open area of the chamber to become enlarged (dilated). As a result, the heart is unable to pump blood as efficiently as usual. To compensate, the heart attempts to increase the amount of blood being pumped through the heart, leading to further thinning and weakening of the cardiac muscle. Over time, this condition results in heart failure. It usually takes many years for symptoms of familial dilated cardiomyopathy to cause health problems. They typically begin in mid-adulthood, but can occur at any time from infancy to late adulthood. Signs and symptoms of familial dilated cardiomyopathy can include an irregular heartbeat (arrhythmia), shortness of breath (dyspnea), extreme tiredness (fatigue), fainting episodes (syncope), and swelling of the legs and feet. In some cases, the first sign of the disorder is sudden cardiac death. The severity of the condition varies among affected individuals, even in members of the same family.

NIH Rare Diseases : 52 Dilated cardiomyopathy (DCM) is a disease of the heart muscle which primarily affects the heart's main pumping chamber, the left ventricle. It is the most common type of cardiomyopathy and typically affects those aged 20 to 60. The left ventricle of affected individuals becomes enlarged (dilated) and cannot pump blood to the body with as much force as a healthy heart can. The heart muscle also has difficulty contracting normally, which can lead to irregular heartbeats (arrhythmia ), blood clots, or sudden death. Over time, the heart becomes weaker and heart failure can occur. While the cause of dilated cardiomyopathy is often unknown (idiopathic), some cases are acquired and roughly half are inherited or familial . Also, DCM can be a feature of many genetic syndromes . Familial dilated cardiomyopathy is most often inherited in an autosomal dominant pattern. Familial dilated cardiomyopathy is caused by mutations in several different genes , most commonly in the TTN gene (found in about 20% of cases). DCM treatment may include medication, pacemakers , implantable cardiac defibrillators , or heart transplantation .

Wikipedia : 74 Dilated cardiomyopathy (DCM) is a condition in which the heart becomes enlarged and cannot pump blood... more...

GeneReviews: NBK1309

Related Diseases for Dilated Cardiomyopathy

Diseases in the Rare Cardiomyopathy family:

Cardiomyopathy, Dilated, 1a Cardiomyopathy, Dilated, 3b
Cardiomyopathy, Dilated, 1b Cardiomyopathy, Dilated, 1e
Cardiomyopathy, Dilated, 1d Cardiomyopathy, Dilated, 1g
Cardiomyopathy, Dilated, 1h Cardiomyopathy, Dilated, 1i
Cardiomyopathy, Dilated, 1j Cardiomyopathy, Dilated, 1k
Cardiomyopathy, Dilated, 1l Cardiomyopathy, Dilated, 1m
Cardiomyopathy, Dilated, 1o Cardiomyopathy, Dilated, 1p
Cardiomyopathy, Dilated, 1q Cardiomyopathy, Dilated, 1w
Cardiomyopathy, Dilated, 1x Cardiomyopathy, Dilated, 1z
Cardiomyopathy, Dilated, 2a Cardiomyopathy, Dilated, 1bb
Cardiomyopathy, Dilated, 1cc Cardiomyopathy, Dilated, 1dd
Cardiomyopathy, Dilated, 1ee Cardiomyopathy, Dilated, 1ff
Cardiomyopathy, Dilated, 1r Cardiomyopathy, Dilated, 1gg
Cardiomyopathy, Dilated, 1u Cardiomyopathy, Dilated, 1v
Cardiomyopathy, Dilated, 1hh Cardiomyopathy, Dilated, 2b
Cardiomyopathy, Dilated, 1ii Cardiomyopathy, Dilated, 1jj
Cardiomyopathy, Dilated, 1kk Cardiomyopathy, Dilated, 1nn
Cardiomyopathy, Dilated, 2c Autoimmune Cardiomyopathy
Dilated Cardiomyopathy 1t Dilated Cardiomyopathy
Lmna-Related Dilated Cardiomyopathy Cardiomyopathy Due to Anthracyclines

Diseases related to Dilated Cardiomyopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 950)
# Related Disease Score Top Affiliating Genes
1 familial isolated dilated cardiomyopathy 37.2 TTN TPM1 TNNT2 TNNI3 TAZ SCN5A
2 cardiomyopathy, dilated, 1e 36.1 TTN TPM1 SCN5A RBM20 MYH7 LMNA
3 atrial standstill 1 35.7 TTN TNNT2 TNNI3 TAZ SCN5A RBM20
4 cardiomyopathy, dilated, 1b 35.7 TTN SCN5A RBM20 MYH7 MYH6 MYBPC3
5 cardiomyopathy, dilated, 3b 35.6 TAZ SCN5A DMD
6 ventricular tachycardia, catecholaminergic polymorphic, 1, with or without atrial dysfunction and/or dilated cardiomyopathy 35.5 SCN5A MYH7 DSP
7 cardiomyopathy, dilated, 1ee 34.8 TPM1 MYH6
8 cardiomyopathy, dilated, 1dd 34.8 TTN RBM20
9 cardiomyopathy, dilated, with woolly hair and keratoderma 34.8 DSP DSG2
10 hypertrophic cardiomyopathy 34.6 TTN TPM1 TNNT2 TNNI3 TAZ SCN5A
11 barth syndrome 34.4 TAZ MYH7 MYH6 MYBPC3
12 myopathy, myofibrillar, 1 34.4 TTN DMD DES BAG3
13 myocarditis 34.3 TNNI3 MYH6 DSP DMD
14 left ventricular noncompaction 34.2 TTN TPM1 TNNT2 TNNI3 TAZ SCN5A
15 peripartum cardiomyopathy 34.2 TTN SCN5A MYH7
16 congenital fiber-type disproportion 34.1 TTN MYH7 MYH6 LMNA DMD
17 heart disease 34.1 TTN TNNT2 TNNI3 TAZ SCN5A MYH7
18 congestive heart failure 34.0 TTN TNNT2 TNNI3 SCN5A PLN MYH7
19 muscular dystrophy 33.6 TTN TNNT2 TNNI3 MYH7 LMNA DMD
20 arrhythmogenic right ventricular cardiomyopathy 33.5 TTN SCN5A RBM20 PLN MYH7 MYH6
21 cardiac conduction defect 33.4 SCN5A PLN MYH7 MYBPC3 LMNA DSP
22 myopathy 33.4 TTN TAZ MYH7 MYH6 LMNA LAMP2
23 mitral valve insufficiency 33.3 TNNT2 TNNI3 MYH7 MYH6 MYBPC3
24 left bundle branch hemiblock 33.3 TNNT2 TNNI3 SCN5A MYBPC3 LMNA DSP
25 cardiac arrest 33.3 TTN TNNT2 SCN5A RBM20 PLN MYH7
26 brugada syndrome 33.3 TTN TPM1 TNNT2 TNNI3 SCN5A RBM20
27 restrictive cardiomyopathy 33.3 TTN TPM1 TNNT2 TNNI3 MYH7 MYH6
28 long qt syndrome 33.2 TTN SCN5A RBM20 MYH7 MYH6 MYBPC3
29 atrioventricular block 33.1 TTN TNNI3 SCN5A MYH7 LMNA DES
30 progressive familial heart block, type ia 32.9 SCN5A MYH7 MYBPC3
31 muscular disease 32.8 TTN TNNT2 TNNI3 TAZ SCN5A MYH7
32 atrial fibrillation 32.8 TTN TNNT2 TNNI3 SCN5A MYH7 MYBPC3
33 ventricular fibrillation, paroxysmal familial, 1 32.7 TNNT2 SCN5A DSP
34 neuromuscular disease 32.7 TTN SCN5A MYH7 MYH6 LMNA DMD
35 syncope 32.6 TTN SCN5A ACTN2
36 wolff-parkinson-white syndrome 32.6 TNNT2 TNNI3 SCN5A MYH7 MYH6 MYBPC3
37 coronary artery anomaly 32.6 TNNT2 TNNI3 SCN5A MYH6
38 cardiomyopathy, familial hypertrophic, 1 32.5 TTN TPM1 TNNT2 TNNI3 MYH7 MYH6
39 heart valve disease 32.5 TNNT2 TNNI3 MYH7 MYH6
40 endocardial fibroelastosis 32.5 TAZ MYH7 CSRP3 ACTN2
41 muscular dystrophy, duchenne type 32.4 TTN TNNT2 TNNI3 DMD
42 atrial heart septal defect 32.4 TTN TNNT2 TNNI3 SCN5A MYH7 MYH6
43 heart septal defect 32.3 TNNT2 TNNI3 MYH7 MYH6
44 sick sinus syndrome 32.2 TTN SCN5A MYH6 LMNA
45 tetralogy of fallot 32.2 TPM1 TNNT2 TNNI3 SCN5A MYH7 MYH6
46 emery-dreifuss muscular dystrophy 32.1 LMNA DMD DES
47 limb-girdle muscular dystrophy 32.1 TTN LMNA DMD
48 aortic valve disease 2 32.1 TTN TNNT2 TNNI3 MYH7 MYH6 MYBPC3
49 muscular dystrophy, congenital, lmna-related 32.0 TTN MYH7 MYH6 LMNA DMD
50 myofibrillar myopathy 31.9 TTN MYH7 MYH6 LMNA DMD DES

Graphical network of the top 20 diseases related to Dilated Cardiomyopathy:



Diseases related to Dilated Cardiomyopathy

Symptoms & Phenotypes for Dilated Cardiomyopathy

Human phenotypes related to Dilated Cardiomyopathy:

58 (show all 17)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 failure to thrive 58 Frequent (79-30%)
2 dyspnea 58 Frequent (79-30%)
3 arrhythmia 58 Frequent (79-30%)
4 congestive heart failure 58 Frequent (79-30%)
5 cough 58 Occasional (29-5%)
6 abnormal levels of creatine kinase in blood 58 Occasional (29-5%)
7 mitral regurgitation 58 Occasional (29-5%)
8 left ventricular hypertrophy 58 Very frequent (99-80%)
9 reduced ejection fraction 58 Frequent (79-30%)
10 atrial fibrillation 58 Frequent (79-30%)
11 palpitations 58 Occasional (29-5%)
12 coronary artery atherosclerosis 58 Excluded (0%)
13 ventricular arrhythmia 58 Occasional (29-5%)
14 elevated pulmonary artery pressure 58 Occasional (29-5%)
15 left ventricular systolic dysfunction 58 Very frequent (99-80%)
16 right ventricular dilatation 58 Frequent (79-30%)
17 left bundle branch block 58 Occasional (29-5%)

MGI Mouse Phenotypes related to Dilated Cardiomyopathy:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.19 BAG3 CSRP3 DES DMD DSG2 DSP
2 cellular MP:0005384 9.9 BAG3 CSRP3 DES DMD DSG2 DSP
3 mortality/aging MP:0010768 9.8 BAG3 CSRP3 DES DMD DSG2 DSP
4 muscle MP:0005369 9.53 BAG3 CSRP3 DES DMD DSG2 DSP

Drugs & Therapeutics for Dilated Cardiomyopathy

Drugs for Dilated Cardiomyopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 181)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Verapamil Approved Phase 4 52-53-9 2520
2
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
3
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
4
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
5
Doxazosin Approved Phase 4 74191-85-8 3157
6
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024
7
Adenosine Approved, Investigational Phase 4 58-61-7 60961
8
Allopurinol Approved Phase 4 315-30-0 2094
9
Enalaprilat Approved Phase 4 76420-72-9 6917719
10
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
11
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
12
Digoxin Approved Phase 4 20830-75-5 30322 2724385
13
Liraglutide Approved Phase 4 204656-20-2 44147092
14
Glucagon Approved Phase 4 16941-32-5
15
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
16
Methyltestosterone Approved Phase 4 58-18-4 6010
17
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 6013 10204
18
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
19
Testosterone enanthate Approved Phase 4 315-37-7 9416
20
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
21
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
22
Saxagliptin Approved Phase 4 361442-04-8 11243969
23
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 4 303-98-0 5281915
24
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
25
Uric acid Investigational Phase 4 69-93-2 1175
26 carnitine Phase 4
27 Vitamins Phase 4
28 Ubiquinone Phase 4
29 Neurotransmitter Agents Phase 4
30 Angiotensin-Converting Enzyme Inhibitors Phase 4
31 Adrenergic alpha-Antagonists Phase 4
32 Antioxidants Phase 4
33 Protective Agents Phase 4
34 calcium channel blockers Phase 4
35 Pharmaceutical Solutions Phase 4
36 Free Radical Scavengers Phase 4
37 Sodium Channel Blockers Phase 4
38 Natriuretic Peptide, Brain Phase 4
39 Cytochrome P-450 CYP3A Inhibitors Phase 4
40 Cytochrome P-450 Enzyme Inhibitors Phase 4
41 Potassium Channel Blockers Phase 4
42 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
43 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
44 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
45 Glucagon-Like Peptide 1 Phase 4
46 Anabolic Agents Phase 4
47 Testosterone 17 beta-cypionate Phase 4
48 Androgens Phase 4
49 Antimetabolites Phase 4
50 Calcium, Dietary Phase 4

Interventional clinical trials:

(show top 50) (show all 285)
# Name Status NCT ID Phase Drugs
1 Prospective, Randomized Comparison of Therapy With Verapamil or Carvedilol on Long-Term Outcomes of Patients With Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy Unknown status NCT00374465 Phase 4 Verapamil;Carvedilol
2 Prospective, Randomized Comparison of Therapy With Verapamil or Carvedilol on Long-Term Outcomes of Patients With Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy Unknown status NCT00348530 Phase 4 Verapamil
3 Identification of Carnitine-responsive Cardiomyopathy and Myopathy in Adult Patients With Dilated and/or Hypertrophic Cardiomyopathy and Limb Girdle Weakness. Unknown status NCT01904396 Phase 4 Carnitine
4 A DANish Randomized, Controlled, Multicenter Study to Assess the Efficacy of Implantable Cardioverter Defibrillator in Patients With Non-ischemic Systolic Heart Failure on Mortality. The DANISH Study Unknown status NCT00541268 Phase 4
5 (MitraClip in Non-Responders to Cardiac Resynchronization Therapy) Unknown status NCT02592889 Phase 4
6 Effect of Coenzyme Q10 (Ubiquinone) Supplementation on Ventricular Function of Children With Idiopathic Dilated Cardiomyopathy.A Randomised Clinical Trial Completed NCT02115581 Phase 4 Coenzyme Q10;Placebo
7 Efficacy and Safety Study of Supramaximal Titrated Inhibition of RAAS in Idiopathic Dilated Cardiomyopathy Completed NCT01917149 Phase 4 Benazepril;Valsartan;Metoprolol
8 Beta-blocker Effect on Structural Remodeling and Gene Expression in the Failing Human Heart Completed NCT01798992 Phase 4 Carvedilol;Metoprolol succinate;Metoprolol succinate + doxazosin
9 Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve Completed NCT03249272 Phase 4 Regadenoson;Adenosine
10 A Multi-center, Randomized, Double, Placebo-controlled, Parallel Group Study of Improving Heart Function and Immunoregulation Effects of Qiliqiangxin Capsule in Patients With Dilated Cardiomyopathy Completed NCT01293903 Phase 4 Qiliqiangxin capsule;Placebo
11 ACC - Atrial Contribution to CRT Completed NCT00180323 Phase 4
12 Effect of Aldosterone on Energy Starvation in Heart Failure Completed NCT00574119 Phase 4 spironolactone
13 Phase 4. Study of Cardiac Resynchronization Therapy in Patients With Permanent Atrial Fibrillation. Completed NCT01181414 Phase 4 Beta blocker/digoxine/amiodarone
14 Effects of Allopurinol on Diastolic Function in Chronic Heart Failure Patients Completed NCT00477789 Phase 4 allopurinol
15 Effects of Early Statin Treatment on Symptomatic Heart Failure and Ischemic Events After Acute Myocardial Infarction. The MUSASHI-AMI: A Multicenter Randomized Controlled Trial Completed NCT00128024 Phase 4 lipid-lowering treatment
16 Effect of the Angiotensin II Receptor Antagonist Irbesartan on Insulin Sensitivity and Metabolic Profile in Patients With Chronic Heart Failure Completed NCT00347087 Phase 4 Irbesartan
17 Effects of Testosterone on Myocardial Repolarization in Patients With Hypogonadism With/Without Chronic Heat Failure (NYHA Class I-II) Completed NCT03126656 Phase 4 Testosterone Undecanoate
18 A Randomized Trial of Carvedilol After Renin-angiotensin System Inhibition in Chronic Chagas Cardiomyopathy Completed NCT01557140 Phase 4 RASi plus carvedilol
19 Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus Completed NCT01761318 Phase 4 Liraglutide;Liraglutide - Placebo
20 Pulse Reduction On Beta-blocker and Ivabradine Therapy Recruiting NCT02973594 Phase 4 Ivabradine;Placebo
21 Olmesartan Effect on Myocardial Viability of Patients With Dilated Cardiomyopathy Active, not recruiting NCT04174456 Phase 4 Olmesartan 20 Mg Oral Tablet
22 Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy-- a Multicenter Randomized Control Trial Not yet recruiting NCT02948998 Phase 4 Spironolactone
23 Effect of Saxagliptin Treatment on Myocardial Fat Content, Left Ventricular Function, and Monocyte Inflammation in Patients With Impaired Glucose Tolerance Terminated NCT01548651 Phase 4 Saxagliptin;Placebo
24 CArdiac Sarcoidosis Response TO steRoids (CASTOR) Trial Withdrawn NCT01210677 Phase 4 Prednisone
25 Regression of Fatty Heart by Valsartan Therapy Withdrawn NCT00745953 Phase 4 Valsartan;Hydrochlorothiazide
26 Follow-up Safety Trial in Children With Chronic Heart Failure Therapy Receiving Orodispersible Minitablets of Enalapril Unknown status NCT02654678 Phase 2, Phase 3 Enalapril Orodispersible Minitablet
27 Orodispersible Minitablets of Enalapril in Children With Heart Failure Due to Dilated Cardiomyopathy Unknown status NCT02652728 Phase 2, Phase 3 Enalapril Orodispersible Minitablet
28 A Prospective, Placebo-controlled, Double-blind, Randomized Study to Compare Hydralazine-isosorbide-dinitrate(HYIS) Versus Placebo on Top of Std Care in African Patients With Acute Heart Failure (AHF) and Left Ventricular Dysfunction Unknown status NCT01822808 Phase 3 Hydralazine;Isosorbide Dinitrate
29 Orodispersible Minitablets of Enalapril in Young Children With Heart Failure Due to Congenital Heart Disease Unknown status NCT02652741 Phase 2, Phase 3 Enalapril Orodispersible Minitablet
30 Cardiovascular Health Investigation and Collaboration From Countries of America to Assess the Markers and Outcomes of Chagas Disease (CHICAMOCHA-3) - EQUITY (Equivalence of Usual Interventions for Trypanosomiasis) Unknown status NCT02369978 Phase 2, Phase 3 Nifurtimox;Benznidazole;Placebo
31 Honey Supplementation in Children With Idiopathic Dilated Cardiomyopathy: A Randomized Controlled Study Completed NCT02987322 Phase 2, Phase 3
32 Multicenter Randomized Study Of Cell Therapy In Cardiopathies - Dilated Cardiomyopathy Completed NCT00333827 Phase 3 optimal therapy for cardiaca failure
33 Autologous Transplantation of Bone Marrow Mononuclear Stem-Cells for Dilated Cardiomyopathy: Randomized Clinical Trial Completed NCT00743639 Phase 2, Phase 3
34 Effects of n-3 Polyunsaturated Fatty Acids (PUFAs) on Left Ventricular Function and Functional Capacity in Patients With Dilated Cardiomyopathy Completed NCT01223703 Phase 3 n-3 PUFAs;Placebo
35 A Phase III Study of the Effect of Rosuvastatin on Left Ventricular Remodeling and Inflammatory Markers in Heart Failure Completed NCT00505154 Phase 3 Rosuvastatin;placebo
36 Repetitive Intramyocardial CD34+ Cell Therapy in Dilated Cardiomyopathy Completed NCT02248532 Phase 2, Phase 3
37 A Randomized, Controlled Study to Evaluate the Safety and Cardiovascular Effects of Algisyl-LVR™ as a Method of Left Ventricular Augmentation in Patients With Dilated Cardiomyopathy (AUGMENT-HF) Completed NCT01311791 Phase 2, Phase 3 Standard medical therapy
38 The Acute Effects of the Angiotensin-converting Enzyme Inhibitor Enalaprilat on Flow Distribution After the Bidirectional Cavopulmonary Connection Completed NCT00741156 Phase 3 Enalaprilat
39 Effects of Growth Hormone on Exercise Capacity and Cardiopulmonary Performance in Patients With Chronic Heart Failure Completed NCT00501514 Phase 3 Growth hormone
40 Carvedilol Effect in Preventing Chemotherapy - Induced Cardiotoxicity. A Randomized Double Blind Study. Completed NCT01724450 Phase 3 Carvedilol;Placebo
41 Beta-Blocker Evaluation in Survival Trial (BEST) Completed NCT00000560 Phase 3 adrenergic beta antagonists
42 Prevention of Left Ventricular Dysfunction With Enalapril and Carvedilol in Patients Submitted to Intensive Chemotherapy for the Treatment of Malignant Hemopathies Completed NCT01110824 Phase 3 Enalapril and carvedilol
43 A Phase III, Double-blinded, Single Center, Randomized, Placebo Controlled Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Single Intravenous Dose of Allogeneic Ischemia Tolerant Human Mesenchymal Bone Marrow Cells to Subjects With Acute Myocardial Infarction Completed NCT02672267 Phase 3
44 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Hemodynamic and Clinical Effects of Natrecor (Nesiritide) Compared With Nitroglycerin Therapy for Symptomatic Decompensated CHF, The VMAC Trial: Vasodilation in the Management of Acute Congestive Heart Failure Completed NCT00270374 Phase 3 nesiritide
45 Prospective Evaluation Of Biventricular Pacing In Patients With Left Ventricular Dysfunction After Cardiovascular Surgery Completed NCT00321295 Phase 3
46 A Phase 3, Multinational, Randomized, Placebo-Controlled Study of ARRY-371797 in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation Recruiting NCT03439514 Phase 3 ARRY-371797
47 Impact of Continues Positive Airway Pressure Treatment in Patients With Dilated Cardiomyopathy and Obstructive Sleep Apnea (RIDA) Recruiting NCT02989181 Phase 3
48 Resveratrol: A Potential Anti- Remodeling Agent in Heart Failure, From Bench to Bedside (RES-HF) Recruiting NCT01914081 Phase 3
49 Bisoprolol for Early Cardiomyopathy in Duchenne Muscular Dystrophy: a Randomized, Controlled Trial Recruiting NCT03779646 Phase 2, Phase 3 Bisoprolol Fumarate
50 PHOspholamban RElated CArdiomyopathy STudy - Intervention (Efficacy Study of Eplerenone in Presymptomaticphospholamban R14del Carriers) Active, not recruiting NCT01857856 Phase 3 Eplerenone

Search NIH Clinical Center for Dilated Cardiomyopathy

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Inamrinone
inamrinone lactate

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Dilated Cardiomyopathy cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: cardiomyopathy, dilated

Genetic Tests for Dilated Cardiomyopathy

Genetic tests related to Dilated Cardiomyopathy:

# Genetic test Affiliating Genes
1 Primary Dilated Cardiomyopathy 29 ABCC9 ANKRD1 BAG3 DES DSG2 FKTN LDB3 LMNA MYBPC3 MYH6 NEXN PLN PSEN1 PSEN2 RBM20 SGCD TAZ TCAP TMPO TNNT2 TTN VCL
2 Dilated Cardiomyopathy 29
3 Familial Dilated Cardiomyopathy 29

Anatomical Context for Dilated Cardiomyopathy

MalaCards organs/tissues related to Dilated Cardiomyopathy:

40
Heart, Bone, Testes, T Cells, Bone Marrow, Endothelial, Skeletal Muscle
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Dilated Cardiomyopathy:
# Tissue Anatomical CompartmentCell Relevance
1 Heart Left Ventricle Cardiomyocytes Affected by disease, potential therapeutic candidate
2 Heart Myocardium Cardiomyocytes Affected by disease
3 Blood Cord Blood Mesenchymal Stem Cells Potential therapeutic candidate
4 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Dilated Cardiomyopathy

Articles related to Dilated Cardiomyopathy:

(show top 50) (show all 16332)
# Title Authors PMID Year
1
Dilated Cardiomyopathy Overview 61 6
20301486 2007
2
Cardiomyopathy, familial dilated. 61 6
16839424 2006
3
Multigenic Disease and Bilineal Inheritance in Dilated Cardiomyopathy Is Illustrated in Nonsegregating LMNA Pedigrees. 61 24
30012837 2018
4
The Rationale and Timing of Molecular Genetic Testing for Dilated Cardiomyopathy. 61 24
26518443 2015
5
A novel human R25C-phospholamban mutation is associated with super-inhibition of calcium cycling and ventricular arrhythmia. 61 24
25852082 2015
6
Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease. 61 24
25589632 2015
7
The landscape of genetic variation in dilated cardiomyopathy as surveyed by clinical DNA sequencing. 61 24
24503780 2014
8
Dilated cardiomyopathy: the complexity of a diverse genetic architecture. 61 24
23900355 2013
9
Exome sequencing and genome-wide linkage analysis in 17 families illustrate the complex contribution of TTN truncating variants to dilated cardiomyopathy. 61 24
23418287 2013
10
Truncations of titin causing dilated cardiomyopathy. 61 24
22335739 2012
11
HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). 6
21810866 2011
12
Update 2011: clinical and genetic issues in familial dilated cardiomyopathy. 61 24
21492761 2011
13
Clinical and genetic issues in dilated cardiomyopathy: a review for genetics professionals. 61 24
20864896 2010
14
Common genetic polymorphisms in pre-microRNAs were associated with increased risk of dilated cardiomyopathy. 61 46
20488170 2010
15
Rare variant mutations in pregnancy-associated or peripartum cardiomyopathy. 61 24
20458009 2010
16
Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. 61 24
20458010 2010
17
The genetics of dilated cardiomyopathy. 61 24
20186049 2010
18
Coding sequence rare variants identified in MYBPC3, MYH6, TPM1, TNNC1, and TNNI3 from 312 patients with familial or idiopathic dilated cardiomyopathy. 61 24
20215591 2010
19
Use of genetics in the clinical evaluation of cardiomyopathy. 61 24
19996403 2009
20
Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy. 61 24
19808347 2009
21
Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity. 61 24
19095136 2008
22
Coding sequence mutations identified in MYH7, TNNT2, SCN5A, CSRP3, LBD3, and TCAP from 313 patients with familial or idiopathic dilated cardiomyopathy. 61 24
19412328 2008
23
Dilated cardiomyopathy presenting during fetal life. 61 24
16014190 2005
24
Clinical and genetic issues in familial dilated cardiomyopathy. 61 24
15808750 2005
25
Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). 24
29904160 2018
26
Use and interpretation of genetic tests in cardiovascular genetics. 24
20937756 2010
27
Connexin 43 remodeling induced by LMNA gene mutation Glu82Lys in familial dilated cardiomyopathy with atrial ventricular block. 54 61
20497714 2010
28
The p.G154S mutation of the alpha-B crystallin gene (CRYAB) causes late-onset distal myopathy. 54 61
20171888 2010
29
Heart failure-associated changes in RNA splicing of sarcomere genes. 54 61
20124440 2010
30
Dilated cardiomyopathy alters the expression patterns of CAR and other adenoviral receptors in human heart. 54 61
19957088 2010
31
A novel LMNA mutation (R189W) in familial dilated cardiomyopathy: evidence for a 'hot spot' region at exon 3: a case report. 54 61
20307303 2010
32
Familial dilated cardiomyopathy secondary to dystrophin splice site mutation. 54 61
20206892 2010
33
Morphological analysis of 13 LMNA variants identified in a cohort of 324 unrelated patients with idiopathic or familial dilated cardiomyopathy. 54 61
20160190 2010
34
Identification of a new lamin A/C mutation in a Chinese family affected with atrioventricular block as the prominent phenotype. 54 61
20155465 2010
35
Prognostic value of tissue Doppler right ventricular systolic and diastolic function indexes combined with plasma B-type natriuretic Peptide in patients with advanced heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. 54 61
20102927 2010
36
Mechanism of right precordial ST-segment elevation in structural heart disease: excitation failure by current-to-load mismatch. 54 61
20022821 2010
37
Reduced glucose transporter GLUT4 in skeletal muscle predicts insulin resistance in non-diabetic chronic heart failure patients independently of body composition. 54 61
18778861 2010
38
Cardiac sodium channel Na(v)1.5 and interacting proteins: Physiology and pathophysiology. 54 61
19744495 2010
39
Novel mutations in beta-myosin heavy chain, actin and troponin-I genes associated with dilated cardiomyopathy in Indian population. 54 61
20086309 2009
40
R25G mutation in exon 1 of LMNA gene is associated with dilated cardiomyopathy and limb-girdle muscular dystrophy 1B. 54 61
20092787 2009
41
[LMNA gene and dilated cardiomyopathy]. 54 61
20193191 2009
42
The signal transduction cascade regulating the expression of the gap junction protein connexin43 by beta-adrenoceptors. 54 61
19719782 2009
43
Stress-induced dilated cardiomyopathy in a knock-in mouse model mimicking human titin-based disease. 54 61
19406126 2009
44
Stimulation of cardiac beta-adrenoceptors targets connexin 43. 54 61
19719781 2009
45
Clinical and functional characterization of TNNT2 mutations identified in patients with dilated cardiomyopathy. 54 61
20031601 2009
46
Validation of high-resolution DNA melting analysis for mutation scanning of the LMNA gene. 54 61
19318026 2009
47
A novel mutation in the G4.5 (TAZ) gene in a Greek patient with Barth syndrome. 54 61
19261493 2009
48
Lamin A/C deficiency as a cause of familial dilated cardiomyopathy. 54 61
19384091 2009
49
Acute dilated cardiomyopathy in a patient with deficiency of long-chain 3-hydroxyacyl-CoA dehydrogenase. 54 61
19083141 2009
50
Comprehensive mutation scanning of LMNA in 268 patients with lone atrial fibrillation. 54 61
19427440 2009

Variations for Dilated Cardiomyopathy

ClinVar genetic disease variations for Dilated Cardiomyopathy:

6 (show top 50) (show all 1236) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 LMNA NM_170707.4(LMNA):c.1086del (p.Leu363fs)deletion Pathogenic 155806 rs58389804 1:156105840-156105840 1:156136049-156136049
2 LMNA NM_170707.3(LMNA):c.(?_1)_(356_?)del (p.(?))deletion Pathogenic 180106 1:156084710-156085065 1:156114919-156115274
3 ACTN2 NM_001103.3(ACTN2):c.355G>A (p.Ala119Thr)SNV Pathogenic 162727 rs727502886 1:236882307-236882307 1:236719007-236719007
4 TTN NM_001267550.2(TTN):c.80716C>T (p.Arg26906Ter)SNV Pathogenic 180010 rs727505284 2:179430143-179430143 2:178565416-178565416
5 TTN NM_001267550.2(TTN):c.49648+2deldeletion Pathogenic 179411 rs727504851 2:179477886-179477886 2:178613159-178613159
6 SCN5A NM_198056.2(SCN5A):c.3995del (p.Pro1332fs)deletion Pathogenic 179338 rs727504801 3:38601888-38601888 3:38560397-38560397
7 LAMP2 NM_013995.2(LAMP2):c.1020del (p.Gly341fs)deletion Pathogenic 178999 rs727504597 X:119575658-119575658 X:120441803-120441803
8 LMNA NM_170707.4(LMNA):c.710T>C (p.Phe237Ser)SNV Pathogenic 180404 rs730880132 1:156104666-156104666 1:156134875-156134875
9 TAZ NM_000116.5(TAZ):c.708_709TG[1] (p.Val237fs)short repeat Pathogenic 177908 rs727504394 X:153649005-153649006 X:154420666-154420667
10 TNNT2 NM_001276345.2(TNNT2):c.547C>T (p.Arg183Trp)SNV Pathogenic 228409 rs727503512 1:201332477-201332477 1:201363349-201363349
11 BAG3 NM_004281.3(BAG3):c.925C>T (p.Arg309Ter)SNV Pathogenic 228322 rs869248137 10:121435991-121435991 10:119676479-119676479
12 MYBPC3 NM_000256.3(MYBPC3):c.2504del (p.Arg835fs)deletion Pathogenic 228369 rs876657704 11:47359040-47359040 11:47337489-47337489
13 RBM20 NM_001134363.3(RBM20):c.1913C>T (p.Pro638Leu)SNV Pathogenic 268 rs267607003 10:112572068-112572068 10:110812310-110812310
14 MYBPC3 NM_000256.3(MYBPC3):c.1624G>C (p.Glu542Gln)SNV Pathogenic 8608 rs121909374 11:47364129-47364129 11:47342578-47342578
15 TNNT2 NM_001276345.2(TNNT2):c.451C>T (p.Arg151Trp)SNV Pathogenic 12414 rs74315379 1:201333464-201333464 1:201364336-201364336
16 SCN5A NM_198056.2(SCN5A):c.4783G>C (p.Asp1595His)SNV Pathogenic 9406 rs137854607 3:38595800-38595800 3:38554309-38554309
17 PLN NM_002667.5(PLN):c.25C>T (p.Arg9Cys)SNV Pathogenic 13636 rs111033559 6:118880109-118880109 6:118558946-118558946
18 LMNA NM_170707.4(LMNA):c.16C>T (p.Gln6Ter)SNV Pathogenic 14477 rs61046466 1:156084725-156084725 1:156114934-156114934
19 LMNA NM_170707.4(LMNA):c.585C>G (p.Asn195Lys)SNV Pathogenic 14483 rs28933091 1:156104265-156104265 1:156134474-156134474
20 LMNA NM_170707.4(LMNA):c.608A>G (p.Glu203Gly)SNV Pathogenic 14484 rs28933092 1:156104288-156104288 1:156134497-156134497
21 LMNA NM_170707.4(LMNA):c.1824C>T (p.Gly608=)SNV Pathogenic 14500 rs58596362 1:156108404-156108404 1:156138613-156138613
22 MYH7 NM_000257.4(MYH7):c.1594T>C (p.Ser532Pro)SNV Pathogenic 14108 rs121913642 14:23897088-23897088 14:23427879-23427879
23 TPM1 NM_001018005.2(TPM1):c.688G>A (p.Asp230Asn)SNV Pathogenic 31884 rs199476317 15:63354462-63354462 15:63062263-63062263
24 SCN5A NM_198056.2(SCN5A):c.665G>A (p.Arg222Gln)SNV Pathogenic 39444 rs45546039 3:38655272-38655272 3:38613781-38613781
25 TAZ NM_000116.5(TAZ):c.718G>C (p.Gly240Arg)SNV Pathogenic 42266 rs387907218 X:153649015-153649015 X:154420676-154420676
26 MYBPC3 NM_000256.3(MYBPC3):c.2096del (p.Pro699fs)deletion Pathogenic 42596 rs397515947 11:47360927-47360927 11:47339376-47339376
27 MYBPC3 NM_000256.3(MYBPC3):c.551dup (p.Lys185fs)duplication Pathogenic 42771 rs397516059 11:47371427-47371428 11:47349876-47349877
28 TNNI3 NM_000363.5(TNNI3):c.544G>A (p.Glu182Lys)SNV Pathogenic 43392 rs397516355 19:55665403-55665403 19:55154035-55154035
29 TNNT2 NM_001276345.2(TNNT2):c.422G>A (p.Arg141Gln)SNV Pathogenic 43637 rs397516464 1:201333493-201333493 1:201364365-201364365
30 DES NM_001927.4(DES):c.38C>T (p.Ser13Phe)SNV Pathogenic 44260 rs62636495 2:220283222-220283222 2:219418500-219418500
31 PLN NM_002667.5(PLN):c.37_39AGA[1] (p.Arg14del)short repeat Pathogenic 44580 rs397516784 6:118880120-118880122 6:118558957-118558959
32 DSP NM_004415.4(DSP):c.1146del (p.Phe382fs)deletion Pathogenic 44852 rs397516913 6:7568014-7568014 6:7567781-7567781
33 LMNA NM_005572.3(LMNA):c.1526dupC (p.Thr510Tyrfs)duplication Pathogenic 48041 rs58013325 1:156106935-156106936 1:156137144-156137145
34 LMNA NM_170707.4(LMNA):c.348dup (p.Lys117fs)duplication Pathogenic 48061 rs267607646 1:156085056-156085057 1:156115265-156115266
35 LMNA NM_170707.4(LMNA):c.673C>T (p.Arg225Ter)SNV Pathogenic 48074 rs60682848 1:156104629-156104629 1:156134838-156134838
36 LMNA NM_170707.4(LMNA):c.700C>T (p.Gln234Ter)SNV Pathogenic 48075 rs267607573 1:156104656-156104656 1:156134865-156134865
37 LMNA NM_170707.4(LMNA):c.958del (p.Leu320fs)deletion Pathogenic 48095 rs397517915 1:156105713-156105713 1:156135922-156135922
38 LMNA NM_170707.4(LMNA):c.961C>T (p.Arg321Ter)SNV Pathogenic 48096 rs267607554 1:156105716-156105716 1:156135925-156135925
39 DES NM_001927.4(DES):c.735+3A>GSNV Pathogenic 66419 rs267607483 2:220285071-220285071 2:219420349-219420349
40 LMNA NM_170707.4(LMNA):c.244G>A (p.Glu82Lys)SNV Pathogenic 66882 rs59270054 1:156084953-156084953 1:156115162-156115162
41 MYH7 NM_000257.4(MYH7):c.1573G>A (p.Glu525Lys)SNV Pathogenic 132925 rs606231324 14:23897714-23897714 14:23428505-23428505
42 RAF1 NM_002880.3(RAF1):c.1922C>T (p.Thr641Met)SNV Pathogenic 142298 rs587777587 3:12626038-12626038 3:12584539-12584539
43 DSP NM_004415.3(DSP):c.2131_2132delAG (p.Ser711Cysfs)deletion Pathogenic 143947 rs587782927 6:7574319-7574320 6:7574084-7574085
44 TTN NM_001267550.2(TTN):c.86363G>A (p.Trp28788Ter)SNV Pathogenic 419359 rs1064793814 2:179424496-179424496 2:178559769-178559769
45 TTN NM_001267550.2(TTN):c.51654C>G (p.Tyr17218Ter)SNV Pathogenic 429894 rs1131691655 2:179474496-179474496 2:178609769-178609769
46 DSP NM_004415.4(DSP):c.3474dup (p.Glu1159fs)duplication Pathogenic 517147 rs727503000 6:7579896-7579897 6:7579663-7579664
47 TTN NM_001267550.2(TTN):c.82657G>T (p.Gly27553Ter)SNV Pathogenic 488810 rs869178171 2:179428202-179428202 2:178563475-178563475
48 LMNA NM_170707.4(LMNA):c.1494G>A (p.Trp498Ter)SNV Pathogenic 520447 rs57730570 1:156106909-156106909 1:156137118-156137118
49 TTN NM_001267550.2(TTN):c.90706G>T (p.Glu30236Ter)SNV Pathogenic 520476 rs974510652 2:179416921-179416921 2:178552194-178552194
50 TTN NM_001267550.2(TTN):c.51581G>A (p.Trp17194Ter)SNV Pathogenic 520481 rs1553692290 2:179474569-179474569 2:178609842-178609842

Expression for Dilated Cardiomyopathy

Search GEO for disease gene expression data for Dilated Cardiomyopathy.

Pathways for Dilated Cardiomyopathy

Pathways related to Dilated Cardiomyopathy according to KEGG:

36
# Name Kegg Source Accession
1 Dilated cardiomyopathy (DCM) hsa05414

Pathways related to Dilated Cardiomyopathy according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.62 TTN TPM1 TNNT2 TNNI3 SCN5A PLN
2
Show member pathways
12.37 TPM1 TNNT2 TNNI3 SCN5A PLN MYH7
3 12.34 TPM1 TNNT2 TNNI3 LMNA DES
4
Show member pathways
11.92 LMNA DSP DSG2 DMD DES ACTN2
5 11.75 PLN MYH7 MYH6
6
Show member pathways
11.72 LMNA DSP DSG2
7 11.7 TPM1 TNNT2 TNNI3 MYH7 MYH6
8
Show member pathways
11.63 TTN TPM1 TNNT2 TNNI3 PLN MYH7
9 11.48 SCN5A PLN LMNA DSP
10 11.47 TTN TPM1 TNNT2 TNNI3 MYH6 MYBPC3
11 11.43 TNNT2 TNNI3 SCN5A MYH6

GO Terms for Dilated Cardiomyopathy

Cellular components related to Dilated Cardiomyopathy according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 sarcolemma GO:0042383 9.72 SCN5A DMD DES
2 stress fiber GO:0001725 9.67 TPM1 MYH7 MYH6 BAG3
3 myofibril GO:0030016 9.65 TNNT2 TNNI3 MYH7 MYH6 DMD
4 lateral plasma membrane GO:0016328 9.63 SCN5A DSG2 DMD
5 intercalated disc GO:0014704 9.62 SCN5A DSP DSG2 DES
6 Z disc GO:0030018 9.61 TTN SCN5A MYH7 MYH6 DMD DES
7 myosin filament GO:0032982 9.58 MYH7 MYH6 MYBPC3
8 contractile fiber GO:0043292 9.54 TNNI3 DES
9 muscle myosin complex GO:0005859 9.52 MYH7 MYH6
10 striated muscle thin filament GO:0005865 9.51 TTN TNNT2
11 fascia adherens GO:0005916 9.49 DSP DES
12 troponin complex GO:0005861 9.48 TNNT2 TNNI3
13 cardiac myofibril GO:0097512 9.46 TNNT2 TNNI3 MYBPC3 DES
14 cardiac Troponin complex GO:1990584 9.43 TNNT2 TNNI3
15 sarcomere GO:0030017 9.28 TTN TPM1 TNNT2 TNNI3 MYH7 MYH6

Biological processes related to Dilated Cardiomyopathy according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 heart development GO:0007507 9.92 TNNI3 TAZ RBM20 CSRP3
2 cellular calcium ion homeostasis GO:0006874 9.83 TNNI3 PLN CSRP3
3 muscle contraction GO:0006936 9.81 TTN TPM1 TNNT2 TNNI3 TAZ MYH7
4 sarcomere organization GO:0045214 9.8 TTN TPM1 TNNT2 MYH6 CSRP3 ACTN2
5 regulation of heart contraction GO:0008016 9.77 TPM1 TNNT2 PLN MYH6 DES
6 skeletal muscle tissue development GO:0007519 9.76 TAZ DMD CSRP3
7 regulation of heart rate GO:0002027 9.76 SCN5A MYH7 MYH6 DMD
8 positive regulation of ATPase activity GO:0032781 9.73 TPM1 TNNT2 MYBPC3
9 regulation of the force of heart contraction GO:0002026 9.73 PLN MYH7 MYH6 CSRP3
10 ventricular cardiac muscle tissue morphogenesis GO:0055010 9.73 TPM1 TNNT2 TNNI3 MYH7 MYH6 MYBPC3
11 regulation of heart rate by cardiac conduction GO:0086091 9.72 SCN5A DSP DSG2
12 skeletal muscle contraction GO:0003009 9.71 TNNT2 TNNI3 MYH7
13 striated muscle contraction GO:0006941 9.71 TTN TNNI3 MYH7 MYH6
14 cardiac muscle tissue development GO:0048738 9.7 TAZ PLN CSRP3
15 muscle cell cellular homeostasis GO:0046716 9.69 LAMP2 DMD BAG3
16 regulation of muscle contraction GO:0006937 9.67 TPM1 TNNT2 TNNI3
17 intermediate filament organization GO:0045109 9.66 DSP DES
18 regulation of ryanodine-sensitive calcium-release channel activity GO:0060314 9.65 PLN DMD
19 cardiac myofibril assembly GO:0055003 9.65 TTN CSRP3
20 negative regulation of ATPase activity GO:0032780 9.65 TNNT2 TNNI3 PLN
21 muscle filament sliding GO:0030049 9.65 TTN TPM1 TNNT2 TNNI3 MYH7 MYH6
22 cardiac muscle hypertrophy in response to stress GO:0014898 9.64 MYH7 MYH6
23 adult heart development GO:0007512 9.64 MYH7 MYH6
24 regulation of cardiac muscle cell contraction GO:0086004 9.63 SCN5A PLN
25 cardiac muscle fiber development GO:0048739 9.63 TTN MYH6
26 regulation of ventricular cardiac muscle cell action potential GO:0098911 9.62 DSP DSG2
27 response to denervation involved in regulation of muscle adaptation GO:0014894 9.61 SCN5A DMD
28 cardiac muscle hypertrophy GO:0003300 9.61 TTN CSRP3
29 chaperone-mediated autophagy GO:0061684 9.6 LAMP2 BAG3
30 bundle of His cell-Purkinje myocyte adhesion involved in cell communication GO:0086073 9.59 DSP DSG2
31 desmosome organization GO:0002934 9.58 DSP DSG2
32 detection of muscle stretch GO:0035995 9.57 TTN CSRP3
33 cardiac muscle contraction GO:0060048 9.36 TTN TPM1 TNNT2 TNNI3 TAZ SCN5A

Molecular functions related to Dilated Cardiomyopathy according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.49 TTN TPM1 TNNT2 TNNI3 SCN5A PLN
2 identical protein binding GO:0042802 9.98 TTN TPM1 PLN MYBPC3 DES CSRP3
3 protein domain specific binding GO:0019904 9.83 TNNI3 SCN5A LAMP2 ACTN2
4 calmodulin binding GO:0005516 9.76 TTN SCN5A MYH7 MYH6
5 cytoskeletal protein binding GO:0008092 9.69 TPM1 DES ACTN2
6 actin filament binding GO:0051015 9.63 TTN TPM1 TNNI3 MYH7 MYH6 ACTN2
7 actin binding GO:0003779 9.61 TPM1 TNNT2 TNNI3 MYH7 MYH6 MYBPC3
8 microfilament motor activity GO:0000146 9.57 MYH7 MYH6
9 structural constituent of cytoskeleton GO:0005200 9.56 TPM1 DSP DMD DES
10 nitric-oxide synthase binding GO:0050998 9.55 SCN5A DMD
11 titin binding GO:0031432 9.54 MYBPC3 ACTN2
12 actinin binding GO:0042805 9.49 TTN CSRP3
13 actin-dependent ATPase activity GO:0030898 9.48 MYH7 MYH6
14 telethonin binding GO:0031433 9.4 TTN CSRP3
15 cell adhesive protein binding involved in bundle of His cell-Purkinje myocyte communication GO:0086083 9.37 DSP DSG2
16 troponin C binding GO:0030172 9.32 TNNT2 TNNI3
17 structural constituent of muscle GO:0008307 9.1 TTN TPM1 MYBPC3 DMD CSRP3 ACTN2

Sources for Dilated Cardiomyopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....